PMC:3724972 / 3111-3768 JSONTXT

{"project":"2_test","denotations":[{"id":"23673515-18413427-63233580","span":{"begin":208,"end":210},"obj":"18413427"},{"id":"23673515-16268808-63233581","span":{"begin":297,"end":299},"obj":"16268808"},{"id":"23673515-18056770-63233582","span":{"begin":301,"end":303},"obj":"18056770"},{"id":"23673515-18413427-63233583","span":{"begin":387,"end":389},"obj":"18413427"},{"id":"23673515-18413427-63233584","span":{"begin":583,"end":585},"obj":"18413427"}],"text":"For most patients with CD, primary treatment is transsphenoidal surgery to remove the pituitary adenoma. However, success rates are variable (reported as 65 to 90 %) and dependent on the surgeon’s expertise [11]. Published 5- and 10-year recurrence rates are as high as 25 and 56 %, respectively [12, 13], and many patients develop deficiencies of other pituitary hormones post-surgery [11]. Patients who fail to achieve or maintain remission require secondary treatment, including radiotherapy and/or adrenalectomy—both of which are associated with subsequent hormone deficiencies [11]. Thus, additional treatment options for patients with CD are required."}